3 completed. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 3 | Completed 3 |
Follow AZD1222: new trials by email Literature Review of AZD1222 trials Research Report on AZD1222
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19 AZD1222, rAd26-S - COVID-19 | Phase 1 / Phase 2 | Completed | R-Pharm | 100 | 2021-09-15 | 2022-06-03 |
| Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19) AZD1222, rAd26-S - COVID-19 | Phase 1 / Phase 2 | Completed | R-Pharm | 100 | 2021-07-13 | 2022-10-26 |
| Study of AZD1222 for the Prevention of COVID-19 in Japan AZD1222, 0.9% (w/v) saline - COVID-19 | Phase 1 / Phase 2 | Completed | AstraZeneca | 256 | 2020-08-23 | 2024-03-01 |
COVID-19 (3) · Coronavirus Infections (1) · Lung Diseases (1) · Respiration Disorders (1)
R-Pharm (2) · AstraZeneca (1)
Japan (1) · Russia (1) · United Arab Emirates (1)
Mikhail Samsonov (2)